ASCO 2025
De-escalating therapy - a step forward
CompassHER2, neoCARHP
ASCO 2025
De-escalating therapy - a step forward
Soft/Text, OASIS-4, TRADE
ASCO 2025
Practice changing results for EBC patients?
NA
ASCO 2025
WSG: HER2+ pooled analysis
WSG-ADAPT
ASCO 2025
Risk according to NATALEE / MonarchE in WSG-ADAPT trial
TRADE
ASCO 2025
Intraoperative dose escalation helps to reach targeted…
ABCSG 45
ASCO 2025
HRD and BRCA status as a new innovative staging system?
TRADE
ASCO 2025
TRADE: Abemaciclib in eBC
EORTC, SURVIVE
ASCO 2025
ctDNA for the early detection of molecular recurrence
ASCENT-04
ASCO 2025
SG + Pembro in aTNBC: a new standard of care?
ASCO 2025
AI and ADCs: Precision diagnostics & safer rechallenge…
CCTG/BCT MA.40/FINER
ASCO 2025
A new standard for endocrine-resistant HR+ MBC?
INAVO120, Veritac-2
ASCO 2025
Triple therapy 1st line | double therapy 2nd line - new…
OptiTROP-Breast05 / BR 18-2 MINI trial / KM-10A/KCSG BR18-13 / PF-07248144
ASCO 2025
New compounds - new approaches: TNBC | HR+ | HER2+
SERENA-6
ASCO 2025
SERENA-6 - a challenging strategy?
EMBER-3, Destiny-Breast06
ASCO 2025
Next-gen endocrine therapies and ADCs: Updates from…
Destiny-Breast09
ASCO 2025
A new standard for the firstline treatment of HER2+…
ASCO 2025
Re-exposition and ILD
ASCO 2025
ABC for metastatic TNBC
VERITAC-2
ASCO 2025
Vepdegestrant for treatment of ER+/HER2- aBC
ASCENT-04
ASCO 2025
New treatment option in first line of metastatic TNBC
ASCENT-04
ASCO 2025
ASCENT-04
CCTG/BCT MA.40/FINER
ASCO 2025
New AKT/PIK3 Antagonist for treatment of mBC after…
ASCENT-04
ASCO 2025
SG + Pembrolizumab might become SOC for PD-L1-positive…
INAVO-120
ASCO 2025
Final OS-Analysis of INAVO-120 trial
DESTINY-Breast09
ASCO 2025
New firstline SOC for HER2+ metastatic BC
CCTG/BCT MA.40/FINER
ASCO 2025
Ipataserib + Fulvestrant improves PFS in PIK3CA-altered…
OptiTROP-Breast05
ASCO 2025
Additional ADC effective for untreated TNBC
SERENA-6
ASCO 2025
Liquid biopsy as a navigator for personalized therapy…
REIN
ASCO 2025
Effective ADC for HER2+ mBC with brain metastases
ASCENT-04
ASCO 2025
A new first-line therapy for TNBC
INAVO120
ASCO 2025
New SOC in first-line treatment for primary endocrine…
MINI
ASCO 2025
Additional chemo-free option for TNBC
OptiTROP-Breast05
ASCO 2025
Sac-TMT for metastatic TNBC
ASCO 2025
T-DXd: Detecting ILD and treat again
ASCENT-04
ASCO 2025
Future new SOC for PD-L1-positive mTNBC
OPERA-01
ASCO 2025
OPERA-01: A randomized, open-label, phase 3 study of…
ASCENT-04
ASCO 2025
Una nuova terapia di prima linea per il TNBC
CCTG/BCT MA.40/FINER
ASCO 2025
Ipatasertib + Fulvestrant mejora la supervivencia libre…
ASCENT-04
ASCO 2025
Nuova opzione di trattamento in prima linea per il TNBC…
ASCENT-04
ASCO 2025
Un nouveau traitement de première ligne pour le TNBC
CCTG/BCT MA.40/FINER
ASCO 2025
Nuovo antagonista di AKT/PIK3 per il trattamento della…
ASCENT-04
ASCO 2025
SG + Pembrolizumab podría convertirse en el tratamiento…
VERITAC-2
ASCO 2025
Vepdegestrant per il trattamento di ER+/HER2- aBC
INAVO-120
ASCO 2025
Analisi finale della OS dello studio INAVO-120
AMPLITUDE, TALAPRO-2
ASCO 2025
PARP-inhibitor combinations in advanced prostate cancer
ASCO 2025
A bright future? Radioligands, hormonal treatment…
ARCHES, ARANOTE, IRONMAN
ASCO 2025
The role of ARPIs in mHSPCThe role of ARPIs in mHSPC
ASCO 2025
Personalized In Situ Immunotherapy SYNC-T Shows High…
ASCO 2025
Localized CSPC - innovations
ASCO 2025
Rebirth of Rucaparib
TheraP / ANZUP 160
ASCO 2025
News of ANZUP trial
EVOLUTION
ASCO 2025
Combination of LU-PSMA and immunotherapy, EVOLUTION…
AMPLITUDE
ASCO 2025
Niraparib + Abiraterone Improves Outcomes in…
EVOLUTION
ASCO 2025
Immuntherapy - an evolution?
MEVPRO-2
ASCO 2025
Adding EZH2 to Enzalutamide to decrease the development…
ARANOTE, ARCHES
ASCO 2025
mHSPC - ADT + NHT updates
ASCO 2025
CAN-2409 Offers First New Option in 20 Years
ASCO 2025
MMAI Model identifies patients who benfit from ARPI in…
IRONMAN
ASCO 2025
Real world data from ironman registry confirms…
ASCO 2025
New way of treatment for PCa
IRONMAN
ASCO 2025
mHSPC - prognostification - indications on integration?
Metacure
ASCO 2025
Stereotactic beam radiation therapy 2.0
ASCO 2025
Artera MMAI score en prediktiv biomarkör i STAMPEDE M0…
IRONMAN
ASCO 2025
Real-world data från Ironman: PSA nivå en viktig…
EVOLUTION
ASCO 2025
Evolution: Kombination av LuPSMA och immunterapi.
CREST
ASCO 2025
Sasanlimab + BCG: Practice-Changing Potential for…
EV-302
ASCO 2025
Complete but Not Finished: EV+P cCR Data Extend the SOC…
CheckMate 901, JAVELIN Bladder Medley
ASCO 2025
ICI Combos in 1L and Maintenance – Mixed Bags or…
NIAGARA
ASCO 2025
ctDNA Clearance Confirms Added Value of Perioperative…
ENLIGHTED
ASCO 2025
UTUC - enlighted
CheckMate-901
ASCO 2025
Benefit of IO/IO therapy in mUC
ASCO 2025
New nectin-4 ADCs are coming
CREST, NIAGARA, CheckMate 901, Javelin Bladder Medley
ASCO 2025
ASCO 2025 - Highlights for Bladder Cancer
CREST
ASCO 2025
CREST Study: Promising Results with PD-1 Inhibitor…
CheckMate 901, JAVELIN Bladder Medley
ASCO 2025
mUC - new approaches?
NIAGARA
ASCO 2025
A new prognostic factor in bladder cancer?: The case of…
EV-302
ASCO 2025
mUC EVP + subsequent therapies
CREST
ASCO 2025
New option for high-risk NMIBC
CREST
ASCO 2025
Intensive caution of BCG Therapy
EV-302
ASCO 2025
Update on EV-PEM in the EV-302 study
EV-302/KEYNOTE-A39
ASCO 2025
Response matters in advanced urothelial cancer patients…
SSANTROP, CREST
ASCO 2025
The role of sansalimab (+ SG) in BCG-naive and…
NIAGARA
ASCO 2025
NIAGARA study and circulating tumor DNA
SSANTROP, CREST
ASCO 2025
El rol de sansalimab (+ SG) en el carcinoma urotelial…
EV-302/KEYNOTE-A39
ASCO 2025
La respuesta es importante en pacientes con cáncer…
ARC-20, LITESPARK-004
ASCO 2025
HIF alfa sigue siendo una diana interesante en el RCC y…
CREST, NIAGARA, CheckMate 901, Javelin Bladder Medley
ASCO 2025
ASCO 2025 - Στιγμιότυπα για τον καρκίνο της ουροδόχου…
NIAGARA
ASCO 2025
¿Un nuevo factor pronóstico en el cáncer de vejiga? El…
ASCO 2025
De nouveaux ADC pour la nectine-4 arrivent
PDIGREE
ASCO 2025
PDIGREE: Real-Life Answers for Post-Ipi/Nivo Decisions
CheckMate 214
ASCO 2025
9 Years of CheckMate 214 – Is Nivo + Ipi Still Holding…
IMmotion010, KEYNOTE 564
ASCO 2025
Who Really Benefits? Pembro’s Solid, Atezo’s Still…
ARC-20
ASCO 2025
Casdatifan + Cabo – Too Early to Call It a Game…
ARC-20, LITESPARK-004
ASCO 2025
HIF alpha still an interesting target in RCC and other…
KEYNOTE-564
ASCO 2025
5-Year OS data from the KEYNOTE-564 study
CheckMate 214
ASCO 2025
Long-term outcome of Nnivo-Ipi in clear cell RCC
ALLO-316/TRAVERSE
ASCO 2025
Allogeneic CD70 CAR T Cells in refractory RCC
STELLAR-002
ASCO 2025
Zanzalitinib + Nivolumab +/- Relatlimab in Front-line…
PDIGREE
ASCO 2025
First lession
CheckMate 214, PDIGREE
ASCO 2025
Nivo + Ipi - Update & Insights
CheckMate 816, NeoADAURA, CheckMate 77T
ASCO 2025
Neoadjuvant Approaches in resectable NSCLC: Insights…
InTRist
ASCO 2025
New synergies? Radiotherapy and IO in Limited-Stage…
AEGEAN, CheckMate 77T
ASCO 2025
cTDNA in periop chemo-IO strategies
CheckMate816
ASCO 2025
CheckMate 816: Update on OS-benefit
CheckMate816
ASCO 2025
CM-816: The OS results are positive and demonstrate…
AEGEAN
ASCO 2025
MRD-analysis of the AEGEAN-trial
NeoADAURA, ALNEO
ASCO 2025
Neadjuvant targeted therapy
DART
ASCO 2025
ctDNA stratification
ALNEO
ASCO 2025
Neoadjuvant Alectinib in resectable stage III NSCLC
CheckMate 816, CheckMate 77T
ASCO 2025
Updates in perioperative strategies in NSCLC
InTRist
ASCO 2025
Chemoimmunotherapy followed by chemoradiotherapy
CheckMate816
ASCO 2025
CM-816 : Les résultats de l'OS sont positifs et…
CheckMate816
ASCO 2025
CheckMate 816 : Mise à jour sur les avantages du…
CheckMate 816, CheckMate 77T
ASCO 2025
Actualizaciones en estrategias perioperatorias en NSCLC
KRYSTAL-7, TROPION-Lung02, CAMPASS
ASCO 2025
New options in First-Line Therapy in metastatic NSCLC
KRYSTAL-7, TROPION-Lung02, CAMPASS
ASCO 2025
Targeting rare mutations in metastatic NSCLC - HER2 and…
SACHI, HERTHENA-Lung02, OptiTROP-Lung03
ASCO 2025
What is the future in the field of EGFR resistance?
HERTHENA-Lung02
ASCO 2025
HER3-DXd: dissapointing negative trial
ASCO 2025
Does the timing of IO-infusion impact survival?
OptiTROP-Lung03
ASCO 2025
ADC as 3L in EGFR
HERTHENA-Lung02
ASCO 2025
Is there still a place for HER3-DXd in advanced NSCLC?
HERTHENA-Lung02
ASCO 2025
HERTHENA-Lung02 unfortunately negative study -…
KRYSTAL-7
ASCO 2025
KRAS G12C: Can immunotherapy improve patient outcome…
KRYSTAL-7
ASCO 2025
GDPase-Inhibition 1st line in KRAS G12C Mut.: Improved…
ASCO 2025
Immunotherapy – before or after 3 p.m.?
ASCO 2025
Benefit of IO is depending on the time of day of…
ASCO 2025
Time of day of immunotherapy is important
SOHO-01
ASCO 2025
Sevarbertinib – an additional option for HER2 exon 20…
RELATIVITY
ASCO 2025
RELA-104-biomarker-analysis
OptiTROP-Lung03
ASCO 2025
ADC in the 3L beats docetaxel
HERTHENA-Lung02, OptiTROP-Lung03
ASCO 2025
Updates on ADCs in EGFR resistance
SACHI
ASCO 2025
Have we MET our target?
TROPION-Lung02
ASCO 2025
TROP2 targets – where is first-line development…
HERTHENA-Lung02
ASCO 2025
Is er nog een plaats voor HER3-DXd in gevorderd NSCLC?
HERTHENA-Lung02
ASCO 2025
HERTHENA-Lung02 étude malheureusement négative -…
KRYSTAL-7
ASCO 2025
KRAS G12C: Kan immunotherapie alleen het resultaat voor…
HERTHENA-Lung02, OptiTROP-Lung03
ASCO 2025
Actualizaciones sobre los ADC en la resistencia al EGFR
SACHI
ASCO 2025
Hebben we ons doel gehaald?
IMforte, DeLLphi-304
ASCO 2025
Redefining SCLC: Lubri/Atezo maintenance in 1L,…
IMforte
ASCO 2025
New maintenance therapy for SCLC
DeLLphi-304
ASCO 2025
Taralatamb - the new SOC in 2L treatment
DeLLphi-304
ASCO 2025
Tarlatamab - a new SOC in second line
IMforte
ASCO 2025
The first positive maintenance therapy in SCLC
DeLLphi-304, IMforte
ASCO 2025
New therapies to improve patient survival
DeLLphi-304
ASCO 2025
DeLLphi-304: Dramatic change in 2L-treatment in SCLC
DeLLphi-304
ASCO 2025
DeLLphi-304 : Changement radical dans le traitement de…
DeLLphi-304, IMforte
ASCO 2025
De nouvelles thérapies pour améliorer la survie des…
CHALLENGE
ASCO 2025
Exercise - The new old wonderdrug
NIVOPOSTOP / GORTEC 2018-01
ASCO 2025
LA HNSCC - New neoadjuvant SOC
Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend.
Jetzt gleich den Fragebogen ausfüllen!